Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin plus Sintilimab in HER2-negative metastatic breast cancer
NCT06308939Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Mar 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab, eribulin in breast cancer, sponsored by Zhejiang Cancer Hospital. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
sintilimaberibulin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06308939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06308939.